Advertisement

Topics

Fresh Off New Funding Round, FluGen Plans 3 Clinical Trials for 2018

18:13 EDT 4 Aug 2017 | Xconomy

FluGen, a startup that’s developing an experimental universal influenza vaccine, is in the process of finalizing its first human clinical trial and plans to initiate three more studies next year. Paul Radspinner, co-founder and CEO of Madison, WI-based FluGen, says his company now has data on the 96 patients who were dosed with its RedeeFlu […]

Original Article: Fresh Off New Funding Round, FluGen Plans 3 Clinical Trials for 2018

NEXT ARTICLE

More From BioPortfolio on "Fresh Off New Funding Round, FluGen Plans 3 Clinical Trials for 2018"

Quick Search
Advertisement
 

Relevant Topics

Influenza
Influenza or 'flu' is a respiratory illness associated with infection by influenza virus. Symptoms frequently include headache, fever, cough, sore throat, aching muscles and joints. There is a wide spectrum of severity of illness ranging from min...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...